MedTrace Logo

Evaluating Dactinomycin and Vincristine in Young Patients With Cancer

NCT00674193 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 158

Last updated 2017-05-17

No results posted yet for this study

Summary

This laboratory study is evaluating how well dactinomycin and vincristine work in treating young patients with cancer. Studying samples of blood and urine in the laboratory from patients with cancer may help doctors learn how dactinomycin and vincristine affect the body and how patients will respond to treatment.

Conditions

  • Childhood Acute Lymphoblastic Leukemia
  • Childhood Rhabdomyosarcoma
  • Childhood Soft Tissue Sarcoma
  • Ewing Sarcoma
  • Ewing Sarcoma of Bone
  • Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor (PNET)
  • Unspecified Childhood Solid Tumor, Protocol Specific
  • Wilms Tumor and Other Childhood Kidney Tumors

Interventions

OTHER

pharmacological study

Correlative studies

OTHER

laboratory biomarker analysis

Correlative studies

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Children's Oncology Group

    lead NETWORK

Principal Investigators

  • Jeffrey Skolnik · Children's Oncology Group

Eligibility

Max Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-02-29
Primary Completion
2016-06-30

Countries

  • United States
  • Australia
  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00674193 on ClinicalTrials.gov